Allopurinol kinetics and bioavailability

@article{Appelbaum2004AllopurinolKA,
  title={Allopurinol kinetics and bioavailability},
  author={Steven J. Appelbaum and Michael Mayersohn and Robert T. Dorr and Donald G. Perrier},
  journal={Cancer Chemotherapy and Pharmacology},
  year={2004},
  volume={8},
  pages={93-98}
}
Six normal, healthy adult males received a single dose of allopurinol intravenously, orally in the form of a commercial tablet, and rectally in the form of an extemperaneously prepared suppository (either in a cocoa butter or in polyethylene glycol base). Plasma allopurinol and oxipurinol concentrations were measured over a period of at least 60 h. The following mean (±SD) values were obtained from the intravenous allopurinol experiment: clearance, 9.62±3.49 ml · kg-1 · min-1; Vd, 1.61±0.74 l… CONTINUE READING

3 Figures & Tables

Connections & Topics

Mentioned Connections BETA
Current use of rectal dosage forms as an adjunct in cancer chemotherapy should therefore be re - examined .
Plasma allopurinol and oxipurinol concentrations were measured over a period of at least 60 h. The following mean ( ±SD ) values were obtained from the intravenous allopurinol experiment : clearance , 9.62±3.49 ml · kg-1 · min-1 ; Vd , 1.61±0.74 l / kg ; t1/2 , 1.62 h. Oxipurinol had a mean t1/2 of 16.90 h. The absolute systemic bioavailability of the oral tablet was 67%±23% , while the allopurinol rectal suppositories produced no measurable plasma concentrations of allopurinol or oxipurinol in any of the subjects .
Plasma allopurinol and oxipurinol concentrations were measured over a period of at least 60 h. The following mean ( ±SD ) values were obtained from the intravenous allopurinol experiment : clearance , 9.62±3.49 ml · kg-1 · min-1 ; Vd , 1.61±0.74 l / kg ; t1/2 , 1.62 h. Oxipurinol had a mean t1/2 of 16.90 h. The absolute systemic bioavailability of the oral tablet was 67%±23% , while the allopurinol rectal suppositories produced no measurable plasma concentrations of allopurinol or oxipurinol in any of the subjects .
Plasma allopurinol and oxipurinol concentrations were measured over a period of at least 60 h. The following mean ( ±SD ) values were obtained from the intravenous allopurinol experiment : clearance , 9.62±3.49 ml · kg-1 · min-1 ; Vd , 1.61±0.74 l / kg ; t1/2 , 1.62 h. Oxipurinol had a mean t1/2 of 16.90 h. The absolute systemic bioavailability of the oral tablet was 67%±23% , while the allopurinol rectal suppositories produced no measurable plasma concentrations of allopurinol or oxipurinol in any of the subjects .
Plasma allopurinol and oxipurinol concentrations were measured over a period of at least 60 h. The following mean ( ±SD ) values were obtained from the intravenous allopurinol experiment : clearance , 9.62±3.49 ml · kg-1 · min-1 ; Vd , 1.61±0.74 l / kg ; t1/2 , 1.62 h. Oxipurinol had a mean t1/2 of 16.90 h. The absolute systemic bioavailability of the oral tablet was 67%±23% , while the allopurinol rectal suppositories produced no measurable plasma concentrations of allopurinol or oxipurinol in any of the subjects .
Plasma allopurinol and oxipurinol concentrations were measured over a period of at least 60 h. The following mean ( ±SD ) values were obtained from the intravenous allopurinol experiment : clearance , 9.62±3.49 ml · kg-1 · min-1 ; Vd , 1.61±0.74 l / kg ; t1/2 , 1.62 h. Oxipurinol had a mean t1/2 of 16.90 h. The absolute systemic bioavailability of the oral tablet was 67%±23% , while the allopurinol rectal suppositories produced no measurable plasma concentrations of allopurinol or oxipurinol in any of the subjects .
Plasma allopurinol and oxipurinol concentrations were measured over a period of at least 60 h. The following mean ( ±SD ) values were obtained from the intravenous allopurinol experiment : clearance , 9.62±3.49 ml · kg-1 · min-1 ; Vd , 1.61±0.74 l / kg ; t1/2 , 1.62 h. Oxipurinol had a mean t1/2 of 16.90 h. The absolute systemic bioavailability of the oral tablet was 67%±23% , while the allopurinol rectal suppositories produced no measurable plasma concentrations of allopurinol or oxipurinol in any of the subjects .
Plasma allopurinol and oxipurinol concentrations were measured over a period of at least 60 h. The following mean ( ±SD ) values were obtained from the intravenous allopurinol experiment : clearance , 9.62±3.49 ml · kg-1 · min-1 ; Vd , 1.61±0.74 l / kg ; t1/2 , 1.62 h. Oxipurinol had a mean t1/2 of 16.90 h. The absolute systemic bioavailability of the oral tablet was 67%±23% , while the allopurinol rectal suppositories produced no measurable plasma concentrations of allopurinol or oxipurinol in any of the subjects .
Plasma allopurinol and oxipurinol concentrations were measured over a period of at least 60 h. The following mean ( ±SD ) values were obtained from the intravenous allopurinol experiment : clearance , 9.62±3.49 ml · kg-1 · min-1 ; Vd , 1.61±0.74 l / kg ; t1/2 , 1.62 h. Oxipurinol had a mean t1/2 of 16.90 h. The absolute systemic bioavailability of the oral tablet was 67%±23% , while the allopurinol rectal suppositories produced no measurable plasma concentrations of allopurinol or oxipurinol in any of the subjects .
Plasma allopurinol and oxipurinol concentrations were measured over a period of at least 60 h. The following mean ( ±SD ) values were obtained from the intravenous allopurinol experiment : clearance , 9.62±3.49 ml · kg-1 · min-1 ; Vd , 1.61±0.74 l / kg ; t1/2 , 1.62 h. Oxipurinol had a mean t1/2 of 16.90 h. The absolute systemic bioavailability of the oral tablet was 67%±23% , while the allopurinol rectal suppositories produced no measurable plasma concentrations of allopurinol or oxipurinol in any of the subjects .
Plasma allopurinol and oxipurinol concentrations were measured over a period of at least 60 h. The following mean ( ±SD ) values were obtained from the intravenous allopurinol experiment : clearance , 9.62±3.49 ml · kg-1 · min-1 ; Vd , 1.61±0.74 l / kg ; t1/2 , 1.62 h. Oxipurinol had a mean t1/2 of 16.90 h. The absolute systemic bioavailability of the oral tablet was 67%±23% , while the allopurinol rectal suppositories produced no measurable plasma concentrations of allopurinol or oxipurinol in any of the subjects .
Plasma allopurinol and oxipurinol concentrations were measured over a period of at least 60 h. The following mean ( ±SD ) values were obtained from the intravenous allopurinol experiment : clearance , 9.62±3.49 ml · kg-1 · min-1 ; Vd , 1.61±0.74 l / kg ; t1/2 , 1.62 h. Oxipurinol had a mean t1/2 of 16.90 h. The absolute systemic bioavailability of the oral tablet was 67%±23% , while the allopurinol rectal suppositories produced no measurable plasma concentrations of allopurinol or oxipurinol in any of the subjects .
Plasma allopurinol and oxipurinol concentrations were measured over a period of at least 60 h. The following mean ( ±SD ) values were obtained from the intravenous allopurinol experiment : clearance , 9.62±3.49 ml · kg-1 · min-1 ; Vd , 1.61±0.74 l / kg ; t1/2 , 1.62 h. Oxipurinol had a mean t1/2 of 16.90 h. The absolute systemic bioavailability of the oral tablet was 67%±23% , while the allopurinol rectal suppositories produced no measurable plasma concentrations of allopurinol or oxipurinol in any of the subjects .
Current use of rectal dosage forms as an adjunct in cancer chemotherapy should therefore be re - examined .
All Topics